These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 10712088

  • 1. [Approval for recombinant growth factor. Since January 2000, patients with diabetic foot ulcers can be treated with the growth factor becaplermin (Regranex), manufactured with genetic technology].
    Fruhstorfer B.
    Internist (Berl); 2000 Jan; 41(1):A38. PubMed ID: 10712088
    [No Abstract] [Full Text] [Related]

  • 2. Use of Regranex gel for diabetic foot ulcers.
    Piascik P.
    J Am Pharm Assoc (Wash); 1998 Jan; 38(5):628-30. PubMed ID: 9782698
    [No Abstract] [Full Text] [Related]

  • 3. Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers.
    Nagai MK, Embil JM.
    Expert Opin Biol Ther; 2002 Feb; 2(2):211-8. PubMed ID: 11849120
    [Abstract] [Full Text] [Related]

  • 4. Use of topical recombinant human platelet-derived growth factor-BB (becaplermin) in healing of chronic mixed arteriovenous lower extremity diabetic ulcers.
    Miller MS.
    J Foot Ankle Surg; 1999 Feb; 38(3):227-31. PubMed ID: 10384364
    [Abstract] [Full Text] [Related]

  • 5. Healing and preventing the diabetic foot wound: where technology, economics and common sense converge.
    Armstrong DG.
    Indian J Med Sci; 2007 Jun; 61(6):324-5. PubMed ID: 17558094
    [No Abstract] [Full Text] [Related]

  • 6. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy.
    Embil JM, Papp K, Sibbald G, Tousignant J, Smiell JM, Wong B, Lau CY.
    Wound Repair Regen; 2000 Jun; 8(3):162-8. PubMed ID: 10886806
    [Abstract] [Full Text] [Related]

  • 7. Randomized clinical trial comparing OASIS Wound Matrix to Regranex Gel for diabetic ulcers.
    Niezgoda JA, Van Gils CC, Frykberg RG, Hodde JP.
    Adv Skin Wound Care; 2005 Jun; 18(5 Pt 1):258-66. PubMed ID: 15942317
    [Abstract] [Full Text] [Related]

  • 8. The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data.
    Persson U, Willis M, Odegaard K, Apelqvist J.
    Value Health; 2000 Jun; 3 Suppl 1():39-46. PubMed ID: 16464208
    [Abstract] [Full Text] [Related]

  • 9. Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries.
    Ghatnekar O, Persson U, Willis M, Odegaard K.
    Pharmacoeconomics; 2001 Jun; 19(7):767-78. PubMed ID: 11548912
    [Abstract] [Full Text] [Related]

  • 10. Platelet-derived growth factor for diabetic ulcers.
    Med Lett Drugs Ther; 1998 Jul 17; 40(1031):73-4. PubMed ID: 9698702
    [No Abstract] [Full Text] [Related]

  • 11. The future of recombinant growth factors in wound healing.
    Robson MC, Mustoe TA, Hunt TK.
    Am J Surg; 1998 Aug 17; 176(2A Suppl):80S-82S. PubMed ID: 9777977
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers.
    Sibbald RG, Torrance G, Hux M, Attard C, Milkovich N.
    Ostomy Wound Manage; 2003 Nov 17; 49(11):76-84. PubMed ID: 14652415
    [Abstract] [Full Text] [Related]

  • 13. [New developments in the treatment of diabetic foot ulcers].
    Bakker K, Schaper NC.
    Ned Tijdschr Geneeskd; 2000 Feb 26; 144(9):409-12. PubMed ID: 10719543
    [Abstract] [Full Text] [Related]

  • 14. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers.
    Steed DL.
    Plast Reconstr Surg; 2006 Jun 26; 117(7 Suppl):143S-149S; discussion 150S-151S. PubMed ID: 16799381
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study.
    Wieman TJ, Smiell JM, Su Y.
    Diabetes Care; 1998 May 26; 21(5):822-7. PubMed ID: 9589248
    [Abstract] [Full Text] [Related]

  • 16. Growth factors in the treatment of diabetic foot ulcers: new technologies, any promises?
    Papanas N, Maltezos E.
    Int J Low Extrem Wounds; 2007 Mar 26; 6(1):37-53. PubMed ID: 17344201
    [Abstract] [Full Text] [Related]

  • 17. Becaplermin gel (PDGF-BB) as topical wound therapy. Plastic Surgery Educational Foundation DATA Committee.
    Ladin D.
    Plast Reconstr Surg; 2000 Mar 26; 105(3):1230-1. PubMed ID: 10724287
    [Abstract] [Full Text] [Related]

  • 18. Topical platelet-derived growth factor vs placebo therapy of diabetic foot ulcers offloaded with windowed casts: a randomized, controlled trial.
    Ma C, Hernandez MA, Kirkpatrick VE, Liang LJ, Nouvong AL, Gordon II.
    Wounds; 2015 Apr 26; 27(4):83-91. PubMed ID: 25855851
    [Abstract] [Full Text] [Related]

  • 19. Clinical efficacy of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Studies Group.
    Wieman TJ.
    Am J Surg; 1998 Aug 26; 176(2A Suppl):74S-79S. PubMed ID: 9777976
    [Abstract] [Full Text] [Related]

  • 20. Clinical trial report stirs debate.
    Magee G, Ovington LG.
    Adv Skin Wound Care; 2006 Mar 26; 19(2):64; author reply 64, 67. PubMed ID: 16557046
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.